Nama's AI scorecard currently rates Dianthus Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does DNTH report earnings?

Dianthus Therapeutics's next scheduled report is on Mar 9, 2027. Analysts expect EPS of -$1.11.

What is the DNTH price target?

The median analyst price target from 16 analysts is $133.50, with a range of $113.00 – $200.00.

Is DNTH Shariah compliant?

Nama's AAOIFI-style screen reads Dianthus Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Dianthus Therapeutics (DNTH)

Healthcare · Biotechnology · NASDAQ

Dianthus Therapeutics (DNTH) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.84B and a free-cash-flow yield of -3.9%. Over the most recent reported fiscal year, revenue declined 67.3%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +133.0% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-33.0%

How far the last close sits under the highest price of the past five years.

Market cap	$4.84B
Trailing P/E	—
Price / book	4.0
Price / sales	2867.7
FCF yield	-3.9%
Dividend yield	—
Gross margin	100.0%
Operating margin	-8079.1%
Net margin	0.0%
Revenue growth (YoY)	-67.3%
Revenue growth (3-yr annual)	-31.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

DNTH earnings

Next report: Mar 9, 2027 (Q4 2026, EPS estimate -$1.11). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.81	-$0.95	+14.7%	$1.21M
Q2 2026	Aug 4, 2026	-$0.90	-$0.91	+1.1%	$761,000
Q1 2026	May 5, 2026	-$0.85	-$1.10	+22.7%	$463,000
Q4 2025	Mar 9, 2026	-$1.43	-$1.03	-38.8%	$284,000

DNTH analyst price target

Median target $133.50 from 16 analysts, ranging $113.00 – $200.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live DNTH data on Nama Insights →

DNTH FAQ

Is DNTH a buy?: Nama's AI scorecard currently rates Dianthus Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DNTH report earnings?: Dianthus Therapeutics's next scheduled report is on Mar 9, 2027. Analysts expect EPS of -$1.11.
What is the DNTH price target?: The median analyst price target from 16 analysts is $133.50, with a range of $113.00 – $200.00.
Is DNTH Shariah compliant?: Nama's AAOIFI-style screen reads Dianthus Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.